Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 4, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2030

Conditions
HR+/HER2- Breast Cancer
Interventions
DRUG

Neoadjuvant Chemotherapy in Combination with Anlotinib and Benmelstobart

"Group A: Epirubicin + cyclophosphamide + Benmelstobart are administered by intravenous drip once every 3 weeks for a total of 2 cycles, followed by nab-paclitaxel + Benmelstobart administered by intravenous drip once every 3 weeks for a total of 2 cycles. During the treatment period, Anlotinib is simultaneously combined. It is taken orally once a day, before breakfast. Take the medicine continuously for two weeks, then stop taking it for one week. One cycle is 21 days, and there are a total of 3 cycles.~Group B: Nab-paclitaxel + Benmelstobart are administered by intravenous drip once every 3 weeks for a total of 2 cycles, followed by Epirubicin + cyclophosphamide + Benmelstobart, which are administered by intravenous drip once every 3 weeks for a total of 2 cycles. During the treatment period, Anlotinib is also used in combination. It should be taken orally once a day before breakfast, continuously for two weeks, then stop taking it for one week."

Trial Locations (3)

Unknown

RECRUITING

Hangzhou Cancer Hospital, Hangzhou

NOT_YET_RECRUITING

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

First Affiliated Hospital of Zhejiang University

OTHER